Tags

Type your tag names separated by a space and hit enter

Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Arch Dermatol 1995; 131(9):1003-8AD

Abstract

BACKGROUND AND DESIGN

There are no large studies evaluating patients with erythrodermic mycosis fungoides and Sézary syndrome to determine the important prognostic factors that may influence survival. This is important since new treatment modalities have been proposed as superior to existing primary therapies. We performed a retrospective cohort study of 106 patients with erythrodermic mycosis fungoides and Sézary syndrome, followed up in the Stanford (Calif) Mycosis Fungoides Clinic, to define the important prognostic factors in this group.

RESULTS

Patients younger than 65 years have a more favorable survival profile than those 65 years or older (P < .005). Longer duration of symptoms before diagnosis (> or = 10 years) tends to be associated with more favorable prognosis (p = .055). Lymph node stage is significantly correlated with survival; patients with overall stage III disease have more favorable prognosis than those with stage IV disease (P < .001). Patients with circulating Sézary cells in their blood have a significantly worse prognosis than those without (P < .005). Patient sex or race had no significant effect on overall survival outcome. Three distinct prognostic groups were identified, "favorable," "intermediate," and "unfavorable," according to the number of unfavorable prognostic factors (P < .005). The median survival in each group is 10.2, 3.7, and 1.5 years, respectively.

CONCLUSIONS

In patients with erythrodermic mycosis fungoides and Sézary syndrome, the important prognostic factors are patient age at presentation, the overall stage, and peripheral blood involvement. Survival varies widely, depending on these variables. These prognostic factors should be evaluated when analyzing survival and/or treatment efficacy data of these patients.

Authors+Show Affiliations

Department of Dermatology, Stanford (Calif) University School of Medicine, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7661601

Citation

Kim, Y H., et al. "Prognostic Factors in Erythrodermic Mycosis Fungoides and the Sézary Syndrome." Archives of Dermatology, vol. 131, no. 9, 1995, pp. 1003-8.
Kim YH, Bishop K, Varghese A, et al. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol. 1995;131(9):1003-8.
Kim, Y. H., Bishop, K., Varghese, A., & Hoppe, R. T. (1995). Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Archives of Dermatology, 131(9), pp. 1003-8.
Kim YH, et al. Prognostic Factors in Erythrodermic Mycosis Fungoides and the Sézary Syndrome. Arch Dermatol. 1995;131(9):1003-8. PubMed PMID: 7661601.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. AU - Kim,Y H, AU - Bishop,K, AU - Varghese,A, AU - Hoppe,R T, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 1003 EP - 8 JF - Archives of dermatology JO - Arch Dermatol VL - 131 IS - 9 N2 - BACKGROUND AND DESIGN: There are no large studies evaluating patients with erythrodermic mycosis fungoides and Sézary syndrome to determine the important prognostic factors that may influence survival. This is important since new treatment modalities have been proposed as superior to existing primary therapies. We performed a retrospective cohort study of 106 patients with erythrodermic mycosis fungoides and Sézary syndrome, followed up in the Stanford (Calif) Mycosis Fungoides Clinic, to define the important prognostic factors in this group. RESULTS: Patients younger than 65 years have a more favorable survival profile than those 65 years or older (P < .005). Longer duration of symptoms before diagnosis (> or = 10 years) tends to be associated with more favorable prognosis (p = .055). Lymph node stage is significantly correlated with survival; patients with overall stage III disease have more favorable prognosis than those with stage IV disease (P < .001). Patients with circulating Sézary cells in their blood have a significantly worse prognosis than those without (P < .005). Patient sex or race had no significant effect on overall survival outcome. Three distinct prognostic groups were identified, "favorable," "intermediate," and "unfavorable," according to the number of unfavorable prognostic factors (P < .005). The median survival in each group is 10.2, 3.7, and 1.5 years, respectively. CONCLUSIONS: In patients with erythrodermic mycosis fungoides and Sézary syndrome, the important prognostic factors are patient age at presentation, the overall stage, and peripheral blood involvement. Survival varies widely, depending on these variables. These prognostic factors should be evaluated when analyzing survival and/or treatment efficacy data of these patients. SN - 0003-987X UR - https://www.unboundmedicine.com/medline/citation/7661601/Prognostic_factors_in_erythrodermic_mycosis_fungoides_and_the_Sézary_syndrome_ L2 - https://jamanetwork.com/journals/jamadermatology/fullarticle/vol/131/pg/1003 DB - PRIME DP - Unbound Medicine ER -